BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 17049998)

  • 1. Is it possible to predict the long-term response to venlafaxine with the use of biological markers and psychophysiological methods?
    Fountoulakis KN; Iacovides A; Karamouzis M; Gerasimou G; Grammatikos P; Fotiou F; Kaprinis G
    J Affect Disord; 2007 Apr; 99(1-3):155-63. PubMed ID: 17049998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurobiological and psychological correlates of suicidal attempts and thoughts of death in patients with major depression.
    Fountoulakis KN; Iacovides A; Fotiou F; Nimatoudis J; Bascialla F; Ioannidou C; Kaprinis G; Bech P
    Neuropsychobiology; 2004; 49(1):42-52. PubMed ID: 14730200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker?
    Ising M; Horstmann S; Kloiber S; Lucae S; Binder EB; Kern N; Künzel HE; Pfennig A; Uhr M; Holsboer F
    Biol Psychiatry; 2007 Jul; 62(1):47-54. PubMed ID: 17123470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam JD; Shults J
    J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
    Bares M; Kopecek M; Novak T; Stopkova P; Sos P; Kozeny J; Brunovsky M; Höschl C
    J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after lithium augmentation in unipolar depression: focus on HPA system activity.
    Adli M; Bschor T; Bauer M; Lucka C; Lewitzka U; Ising M; Uhr M; Mueller-Oerlinghausen B; Baethge C
    Neuropsychobiology; 2009; 60(1):23-30. PubMed ID: 19684420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression.
    Baune BT; Caliskan S; Todder D
    Hum Psychopharmacol; 2007 Jan; 22(1):1-9. PubMed ID: 17191266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients.
    Binder EB; Künzel HE; Nickel T; Kern N; Pfennig A; Majer M; Uhr M; Ising M; Holsboer F
    Psychoneuroendocrinology; 2009 Jan; 34(1):99-109. PubMed ID: 18829172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venlafaxine-lithium toxicity: suitability for use in the elderly.
    Gillman K
    J Clin Pharm Ther; 2007 Oct; 32(5):529-31. PubMed ID: 17875121
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
    Amsterdam JD; Shults J
    J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder.
    Arnold LM; Meyers AL; Sunderajan P; Montano CB; Kass E; Trivedi M; Wohlreich MM
    Ann Clin Psychiatry; 2008; 20(4):187-93. PubMed ID: 19034749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder.
    Mbaya P; Alam F; Ashim S; Bennett D
    Hum Psychopharmacol; 2007 Apr; 22(3):129-33. PubMed ID: 17397100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
    Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
    Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: long-term results.
    Maina G; Rosso G; Bogetto F
    J Affect Disord; 2009 Apr; 114(1-3):200-7. PubMed ID: 18728001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-treatment anterior cingulate activity as a predictor of antidepressant response to repetitive transcranial magnetic stimulation (rTMS).
    Langguth B; Wiegand R; Kharraz A; Landgrebe M; Marienhagen J; Frick U; Hajak G; Eichhammer P
    Neuro Endocrinol Lett; 2007 Oct; 28(5):633-8. PubMed ID: 17984932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications.
    Vanoli A; Lane C; Harrison C; Steen N; Young A
    J Psychopharmacol; 2008 Jun; 22(4):434-40. PubMed ID: 18635723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF 5-HIAA and DST non-suppression--orthogonal biologic risk factors for suicide in male mood disorder inpatients.
    Jokinen J; Nordström AL; Nordström P
    Psychiatry Res; 2009 Jan; 165(1-2):96-102. PubMed ID: 19062105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.